Oaktree Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Oaktree Capital Management’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,000	Closed	-$1.06M	–	236
2023 Q2	$1.06M	Hold	100,000	–	–	0.01%	225
2023 Q1	$1.04M	Hold	100,000	–	–	0.01%	274
2022 Q4	$1.03M	Hold	100,000	–	–	0.01%	313
2022 Q3	$1M	Hold	100,000	–	–	0.01%	341
2022 Q2	$1M	Hold	100,000	–	–	0.01%	319
2022 Q1	$988K	Buy	+100,000	New	+$987K	0.01%	318

Other funds holding BIOS

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Oaktree Capital Management's BIOS Position: Q3 2023 in Review

Oaktree Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q3 2023, closing a stake of 100,000 shares — an estimated $1.06M sold.

Oaktree Capital Management first reported a position in BIOS in Q1 2022 and held it in 6 quarters. The position peaked at $1.06M in Q2 2023. 30 funds tracked by Wall St. Rank hold BIOS as of Q3 2023.

Oaktree Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Oaktree Capital Management sold 100,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q3 2023, an estimated $1.06M.
Oaktree Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 6 quarters.
Oaktree Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $1.06M in Q2 2023.
30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q3 2023.

Based on Oaktree Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.